XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 2,436 $ 2,177
Accounts receivables, net of allowance for credit losses of $120 million and $126 million as of June 30, 2021 and December 31, 2020 4,488 4,581
Inventories 4,362 4,403
Prepaid expenses 1,022 945
Other current assets 484 710
Assets held for sale 29 189
Total current assets 12,822 13,005
Deferred income taxes 645 695
Other non-current assets 530 538
Property, plant and equipment, net 6,127 6,296
Operating lease right-of-use assets 531 559
Identifiable intangible assets, net 8,120 8,923
Goodwill [1] 20,421 20,624
Total assets 49,195 50,640
Current liabilities:    
Short-term debt 3,530 3,188
Sales reserves and allowances 4,453 4,824
Accounts payables 1,551 1,756
Employee-related obligations 511 685
Accrued expenses 1,807 1,780
Other current liabilities 838 933
Total current liabilities 12,691 13,164
Long-term liabilities:    
Deferred income taxes 932 964
Other taxes and long-term liabilities 2,215 2,240
Senior notes and loans 21,602 22,731
Operating lease liabilities 444 479
Total long-term liabilities 25,193 26,414
Commitments and contingencies, see note 10
Total liabilities 37,884 39,579
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; June 30, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,209 million shares and 1,202 million shares, respectively 57 57
Additional paid-in capital 27,503 27,443
Accumulated deficit (10,662) (10,946)
Accumulated other comprehensive loss (2,446) (2,399)
Treasury shares as of June 30, 2021 and December 31, 2020 — 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 10,324 10,026
Non-controlling interests 987 1,035
Total equity 11,311 11,061
Total liabilities and equity $ 49,195 $ 50,640
[1] Accumulated goodwill impairment as of June 30, 2021 and December 31, 2020 was approximately $25.6 billion.